Replies to post #245437 on Biotech Values

[Mufaso]

VKTX's VK2809 (TRß Agonist) is a prodrug that is inactive until it gets metabolized in the liver. The thought is that this should lead to efficacy at lower dose levels while providing a better safety profile. The current phase 2B VK2809 trial has 1 mg QD, 2.5 mg QD, 2.5 mg QD, 5 mg QOD and 10 mg QOD dosing arms.

For comparison Madrigals's MGL-3196 or Resmetirom (TRß Agonist) was dosed at 100 mg and 80 mg in their MAETRO-NASH study.

Is it any more likely that VK2809 have a better profile for ballooning and inflammation that Resmetirom as a result of using less drug while reducing still reducing steatosis at an comparable rate?

[DewDiligence]

Q for anyone long MDGL—Are you concerned about the discussion in #msg-171169554? If not, why not? TIA